Ankita Aggarwal

Dr. Ankita Aggarwal


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2022 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
Avirup GuhaAvirup Guha
Avirup Guha
AJAnubhav Jain
Anubhav Jain
AAAnkita Aggarwal
Ankita Aggarwal
ADAmit Kumar Dey
Amit Kumar Dey
SDSourbha S. Dani
Sourbha S. Dani
MFMichael Fradley
Michael Fradley
Background: The aim of this study is to assess the burden of AF-related hospitalizations inclusive of inflation-adjusted cost-of-care and length-of-stay (LOS) among cancer patients and the impact of direct current cardioversion (DCCV) on these outcomes. Methods: Using the National Inpatient Sample (NIS), patients hospitalized with either a primary or secondary diagnosis of AF and comorbid cancer were identified and both cost of hospitalization and LOS were evaluated for each group. Subgroup analyses were performed for specific cancer types (breast, lung, colon, prostate and lymphoma), and those receiving DCCV. Results: The prevalence of co-morbid AF was 8.2 million (16%) and 35.5 million (10%) among those with vs. those without cancer, respectively (odds ratio = 1.6, 95% confidence interval = 1.5–1.7; P < 0.001). Over time, both primary and prevalent AF admissions among those with comorbid cancer increased from 1.1% and 12.3% in 2003 to 1.5% and 21% in 2015, respectively. The total cost of hospitalization increased 94.4% among those with AF and comorbid cancer compared to 23.9% among those without cancer. Among the subgroup of patients with comorbid cancer and primary admission for AF undergoing DCCV, length of stay (2.7 vs. 2.2 days; P < 0.001, model 1) and cost of care ($7,093 vs. 6,152; P < 0.001) were both significantly higher. Conclusions: AF related admissions are increasing for all populations especially amongst those patients with a comorbid diagnosis of cancer, including all cancer subtypes evaluated. Among those patients who underwent DCCV, cancer patients had longer length of stay and increased health care costs.

18 November 2020 in Cureus
Verified
Journal Article
Open access
PDF file
AAAnkita Aggarwal
Ankita Aggarwal
AJAnubhav Jain
Anubhav Jain
SSSonali Sachdeva
Sonali Sachdeva
ZKZain I Kulairi
Zain I Kulairi
Sodium-glucose cotransporter-2 (SGLT2) inhibitors assert their role as an anti-diabetic medication by reversibly inhibiting sodium-glucose cotransporters in the renal proximal tubules and resulting in enhanced glucose excretion. Due to their reversible effect on the transporters in the proximal tubule, it is expected that all their metabolic effects, including glucose excretion, should also cease in two to three days, as per their half-life of 10-15 hours. However, it is increasingly being observed that the glycosuric effect of SGLT2 inhibitors persists beyond this duration and, in many cases, exceeds their other known metabolic effects, which resolve sooner. We present a case report of a 53-year-old diabetic male who developed SGLT2 inhibitor-related euglycemic diabetic ketoacidosis (EuDKA) two days after being discharged post a laparoscopic appendectomy procedure. The patient was treated as per the recommended protocols, after which ongoing metabolic acidosis abated, but the patient’s urinary glucose remained on the higher end. We present an up-to-date review of existing evidence on this rare but serious side effect of SGLT2 inhibitors.

14 December 2023 in Cureus
Verified
Journal Article
Open access
PDF file
AAAnkita Aggarwal
Ankita Aggarwal
CWCameron Whitler
Cameron Whitler
AJAnubhav Jain
Anubhav Jain
HPHarshil Patel
Harshil Patel
MZMarcel Zughaib
Marcel Zughaib
Carotid artery stenting (CAS) and carotid artery endarterectomy (CEA) are revascularization options for the management of severe carotid disease in asymptomatic patients. We aimed to compare the peri-procedural outcomes of the two modalities. A systematic review of the databases PUBMED, EBSCO, and Cochrane Library was performed. All the studies that reported periprocedural outcomes (within 30 days) in asymptomatic carotid stenosis patients were included in the meta-analysis. Random effects models with inverse-variance weighting were used to estimate pooled risk ratios (RRs) to compare the outcomes. Fifteen studies (including seven randomized controlled trials) met the inclusion criteria. A total of 15251 patients were included, out of which 6419 (42%) underwent CAS and 8832 (57.9%) underwent CEA. There was no statistical difference in the primary composite outcome of death/stroke/myocardial infarction (MI) (RR 1.02, 95% CI [0.69-1.51], p 0.93). No difference was found in the secondary outcome of all-cause mortality. CAS was associated with a slightly lower risk of MI and cranial nerve palsy. CAS was associated with a slightly higher risk of stroke with no difference in the occurrence of disabling stroke or ipsilateral stroke. In general terms, the study confirms equipoise in the two treatment strategies with a higher risk of MI and cranial nerve palsy with CEA and a higher risk of non-disabling stroke with CAS.